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Abstract
It is quite universally acknowledged by bioethicists, at least in the western world, that respect for the patients’ autonomy, non-malevolence, benefi-
cence, and justice (also called equity) are four core ethical values in medicine. The Ethics Guidelines of key journals in laboratory medicine are not 
explicit about the first three of these values, and even implicitly, they seem to miss values of justice. Health equity being one of the main objectives 
of public health policy across the world, we suggest that values of equity explicitly become part of the Ethics Guidelines of laboratory medicine 
journals. Biochemia Medica could show the way to other medical publishers by incorporating into its Ethics Guidelines these very important core 
bioethical values.
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Medicine is more than pure science like, for exam-
ple, physics, or mathematics: it is also underpinned 
by ethics and values at a society level (1). It is there-
fore paramount for editors of biomedical journal 
to adhere to ethical values. This is probably why 
more and more editors, including in the field of 
laboratory medicine, publish their own Publication 
Ethics Guidelines, such as Clinical Chemistry in 2009 
(2), or Clinical Chemistry and Laboratory Medicine in 
2013 (3), and/or become members of the Commit-
tee on Publication Ethics (COPE) (4), such as Bio-
chemia Medica, Clinica Chimica Acta, Clinical Bio-
chemistry, and a few others. The ethical principles 
and values endorsed by these journals are more or 
less adapted from those of international organiza-
tions such as the International Committee of Medi-
cal Journal Editors (ICMJE) (5), or COPE (4).
However, on careful reading of these Ethics Guide-
lines, including those of COPE, and of ICMJE, one 
can see that, apart from the endorsement of the 
Helsinki rules regarding the protection of subjects 
enrolled in studies, all the other principles and val-
ues related to publication ethics could suit any sci-
entific journal from astronomy to engineering, etc.
Nevertheless, biomedical journals, including those 
in the field of Laboratory Medicine, are supposed 
to be more than purely scientific publications: they 
are also medical journals and as such their articles 
potentially influence medical practice and are like-
ly to contribute to the improvement of public 
health. This is why the Ethics Guidelines of bio-
medical journals, including those of laboratory 
medicine, could be improved by more explicitly in-
corporating some of the quite established core 
ethical principles and values specific to the field of 
medicine.
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Are there core bioethical values in 
medicine and health-care?
It is quite universally acknowledged by bioethicists 
that respect for the patients’ autonomy, non-ma-
leficence, beneficence, and justice (also called eq-
uity) are four core ethical values in medicine (1), 
which are briefly defined below:
1. An autonomous patient acts in accordance 
with self-chosen plans, free from controlling in-
terferences by others.
2. Non-maleficence imposes an obligation not to 
inflict harm on others. Many medical interven-
tions may be both harmful and beneficial, but 
the harms should be proportionate to the ben-
efits.
3. Beneficence means that health-care profession-
als contribute to the welfare of the patients in a 
way that makes sense to the individual patient.
4. Justice, also called equity, means that patients 
in similar positions should be treated in a simi-
lar manner. It is equally true that an injustice in-
volves a wrongful act or omission that denies 
people resources or protections to which they 
have a right.
Are these four core values dealt with in 
current Publication Ethics Guidelines?
Implicitly the answer might be yes regarding non-
maleficence, beneficence, and respect for the pa-
tients’ autonomy. For example, fabrication, falsifi-
cation or mismanagement of primary data can ob-
viously lead to deceptive articles having a strong 
potential to both, deceit patients’ unbiased, in-
formed decisions, and support interventions 
whose clinical harms may outweigh clinical bene-
fits. However this is implicit, not explicit, which 
somewhat weakens these guidelines.
Health equity is one of the main objectives of pub-
lic health policy across the world, as disadvan-
taged populations have poorer health, and poorer 
access to health care (6). This can be problematic 
including in rich countries, for example in the USA 
where worsening inequities have been reported 
by Krieger et al. between 1960 and 2002 (7). The 
Office of Minority Health & Health Equity of the 
Centers for Disease Control and Prevention (CDC) 
of the USA states on its front page on the Internet: 
“The future health of the nation will be determined 
to a large extent by how effectively we work with 
communities to eliminate health disparities among 
those populations experiencing a disproportion-
ate burden of disease, disability, and death. Persis-
tent health disparities in our country are unaccept-
able and correctable” (8). Regarding the coverage 
of equity in publication ethics, a statement similar 
to the one above from the CDC, and highlighting 
the commitment to the elimination of health dis-
parity could help in clarifying the values that bio-
medical journal editors intend to deal with.
Why might it be important to incorporate 
more explicitly core bioethical values 
into Publication Ethics Guidelines? A few 
examples .
1) The example of vitamin D testing
Vitamin D testing has now become one of the 
most frequently ordered laboratory test across the 
world. For example in France, the frequency of 
testing has been multipled by more than 10 times 
in less than one decade, and vitamin D is now on 
the verge of becoming the second most frequent-
ly ordered test just after blood cell counts. Clinical-
ly speaking, it sounds likely that these millions of 
tests have not harmed patients, but it also remains 
to be demonstrated that this huge increase in fre-
quency of testing has improved the health of the 
public (9). The balance between clinical benefits 
and harms (or in other words between benefi-
cience and malevolence) is therefore probably 
neutral. On the other hand, these numerous tests 
are now costing around 150 million Euros each 
year to the French collectivity, just for private labs. 
Such a waste of resource does conflict with values 
of justice, particularly in a country where millions 
of people are poor, and becoming poorer and 
poorer, many of whom becoming more and more 
unable to access to health-care. This huge increase 
of requests being very much connected with their 
promotion by writers of medical articles, it could 
therefore be supposed that if values of justice had 
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clearly been part of Publication Ethics Guidelines, 
then perhaps these writers might have been less 
efficient in their work of promotion. For more de-
tails see section below entitled: “If core bioethical 
principles were explicitely incorporated into Publi-
cation Ethics Guidelines, then wouldn’t such 
guidelines be difficult to implement?”.
2) The example of PSA (prostate-specific 
antigen) testing
If 2,000 men were randomized into two groups of 
1,000 men, one group being screened with PSA 
testing and the other one not being tested, then 
there would probably be as many men dying of 
prostate cancer in each group, or maybe accord-
ing to the most optimistic trials: one death from 
prostate cancer would perhaps be avoided among 
the 1,000 screened men (10). In addition, 20 of the 
1,000 screened men would be treated for prostate 
cancers which would not have caused symptoms. 
Five of these 20 men would have lifelong compli-
cations, including impotence and incontinence. 
Such statistics allow concluding that depending 
on patients’ preferences, the test may be less be-
neficent than malevolent. In addition, PSA being a 
test that is mostly requested in a context of popu-
lation screening, it is not surprising that it is among 
one of the most frequently ordered test in the 
world. For example, PSA testing in France is cost-
ing around 50 million Euros each year to the French 
collectivity just for private labs. This, again, raises 
issues of justice, just as in the vitamin D example 
above. In addition, taking into account the harms, 
and the very serious harms, done to respectively 
20, and 5, of 1,000 patients tested, the question of 
informed consent of the patients (and therefore 
the question of whether or not their autonomy has 
been respected through fair informed consent) 
can very seriously be raised (10). For more details 
see section below entitled: “If core bioethical prin-
ciples were explicitely incorporated into Publica-
tion Ethics Guidelines, then wouldn’t such guide-
lines be difficult to implement?”.
3) The example of conflicts of interest (COI)
It is more and more acknowledged by the medical 
community, that there is some room for improve-
ment regarding the way COI of editors, of review-
ers and of authors of biomedical articles are cur-
rently managed. Current Publication Ethics Guide-
lines generally require that authors of articles de-
clare their COI, which are then published together 
with their articles. As an example of the shortcom-
ings of current Ethics Guidelines, let us note that 
the declarations of the reviewers are generally not 
published with the articles that they review, and 
that the COI of the editors are even less often dis-
closed to the public. The fact that journals are 
more rigorous about COI with authors than with 
both reviewers and editors might reflects a lack of 
awareness about bioethical values. Why? The first 
answer that springs to mind, is that journals prob-
ably do not realize that COI have a strong potential 
to distort the evidence, which in turn can favor in-
terventions whose maleficence may outweigh be-
neficence, with a higher risk that justice and re-
spect for the patient’s autonomy are not properly 
dealt with (see the vitamin D and PSA examples 
above). The 2nd answer that comes to mind is that 
journals probably do not realize the paramount 
importance of virtues such as truthfulness and ve-
racity for health professionals, researchers, and 
biomedical journalists. Having such virtues is in-
deed essential to foster trust, and if we define vir-
tues as personal traits that contribute to a good 
climate of trust between people, where trust is 
taken to be acceptance of being to some degree 
and in some respects, in another’s power, then it 
seems obvious that trustworthiness is essential in 
healthcare (1). Can we expect biomedical articles 
to be more beneficent than malevolent if the trust 
that people may have in this sort of biomedical ev-
idence ends up being destroyed by authors, re-
viewers, or editors being less than fully open (even 
unintentionally) about their COI?
Should medical writers (i .e . medical 
journalists) deal with the same bioethical 
values as health-care professionals?
One could argue that core ethical principles in 
medicine (patient’s autonomy, non-maleficence, 
beneficence and justice) cannot be easily applied 
in Publication Ethics, because medical practice in-
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volves working with patients, and assumes diag-
nosing, treating or preventing conditions or dis-
eases, whereas medical journalism assumes writ-
ing and publishing papers mainly through medical 
journals, without interfering with patients. Al-
though these view may make sense (except per-
haps for medical writers or journalists who are also 
medical practitioners, which is the case of many of 
them), one could counter-argue that:
1. If medicine is more than science, then “Publi-
cation Ethics” should not remain synonymous 
anymore with “Medical-Publication Ethics” in 
the spirit of the writers, of the reviewers, and of 
the editors of medical articles.
2. If laboratory medicine is a medical discipline, 
then bioethical values should be dealt with in 
the same spirit in laboratory medicine publish-
ing as in hepatology and hematology publish-
ing, etc.
3. Writers, reviewers, and editors of medical ar-
ticles, or in other words: medical journalists, 
should always bear in mind that their published 
articles may ultimately be used as evidence by 
the panelists who develop medical practice 
guidelines. The influence of evidence-based 
medicine is already significant on medical prac-
tice and this tendency is likely to be reinforced 
more and more in the future (11,12).
Should laboratory professionals deal 
with the same bioethical values as other 
categories of medical specialists?
One could argue that although laboratory medi-
cine is a medical discipline, laboratory medicine 
specialists generally do not deal with patients but 
rather with patients’ samples (blood, urine, etc). 
Based on this general observation, one may con-
clude that core bioethical values should not apply 
to laboratory specialists. On the other hand, it may 
also be counter-argued that:
1. More and more countries in the world require 
that medical laboratories are accredited accord-
ing to ISO 15189. For example, in France current 
laws say that the very few non-accredited labo-
ratories that still exist in our country will have 
to close within the next few months. Being ac-
credited according to ISO 15189 implies that 
patient’s samples are not supposed to be ac-
cepted by the laboratory without a laboratory 
specialist being aware of the clinical context of 
the patient, so that this medical specialist can 
decide which tests are the most appropriate 
for an individual patient, and then be able to 
interpret the laboratory results for that individ-
ual patient. Therefore it can be said that labora-
tory specialists are more and more dealing with 
the patients in a way that resembles more and 
more to the way physicians deal with patients.
2. In some countries, for example in France, labo-
ratory medicine specialists have an obligation 
to implement the guidelines which are pub-
lished by their governmental organizations, for 
example in France the Haute Autorité de Santé 
(HAS). The HAS does not recommend to mea-
sure Prostate Specific Antigen (PAS) for screen-
ing prostate cancer unless the patient insists 
and gives his formal consent to be screened 
(10), and the HAS recommends to measure vi-
tamin-D only in a limited number of specific 
circumstances (9). As already suggested above 
the bioethical values that are dealt with in 
these two French guidelines (9,10) are mostly 
patient’s autonomy, non-maleficence, benefi-
cence and justice, which adds some weight in 
our view to our own recommendation regard-
ing the incorporations of these core values into 
Publication Ethics Guidelines.
If core bioethical principles were 
explicitly incorporated into Publication 
Ethics Guidelines, then wouldn’t such 
guidelines be difficult to implement?
Guidelines run the risk of being useless if they can-
not be implemented. It sounds indeed reasonable 
and common sense, to argue that before one pub-
lishes guidelines, one should at least identify pos-
sible barriers to implementation, and propose 
practical guidance regarding how the guidelines 
will possibly be implemented.
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One such barrier could be a possible lack of knowl-
edge about bioethics by many editors and by 
many reviewers, as well as by many authors. There-
fore, one of the prerequisites for implementing 
such guidelines would be for medical journals to 
have some editors and/or some reviewers special-
ized in bioethics. This could include university de-
grees in bioethics, as well as training, experience, 
and publications within this discipline. We already 
illustrated above with a few examples (PSA testing, 
vitamin D testing, and COI) that many editors of 
medical journals probably fail to incorporate core 
bioethical values into the papers that they publish 
and the potential adverse consequences of such 
failures.
As another example of possible guidance on how 
these four values should be incorporated into Eth-
ics Guidelines that would be implementable, we 
propose that just like more and more editors-in-
chief require that papers published in journals 
contain a section entitled “Declarations of COI”, 
papers should contain another mandatory section 
entitled “Ethics Review” where the possible impact 
of the paper regarding the four principles should 
systematically be examined by the authors. Thus 
both reviewers, and editors, using their special 
knowledge about, and training/experience in, bio-
ethics would have an opportunity to systematical-
ly review such Ethics Reviews. This might ultimate-
ly lead to a better distinction, ethically speaking, 
between articles that are worth being published, 
and those that need to be revised, or rejected, or 
maybe published with Ethical Provisions.
In conclusion, Biochemia Medica could show the 
way to other medical publishers by incorporating 
into its Publication Ethics Guidelines these very 
important core bioethical principles.
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